Researchers in this 2007 study took a look at the effects that stimulation of the cannabinoid receptors in the central nervous system had on brain inflammation. They induced a model of brain inflammation in rats, and then attempted to treat it using a chemical known as WIN 55,212-2. WIN 55,212-2 is a synthetic cannabinoid which acts in much the same way and on the same receptors as tetrahydrocannabinol. The researchers found that cannabinoid was in fact able to reduce brain inflammation, and suggested that CBr agonists (chemicals which active the brain's CBr receptors) could be used in the treatment of "neurodegenerative diseases associated with chronic neuroinflammation, such as Alzheimer disease."
Though the authors did not mention marijuana directly, it just so happens to provide the user with ample amounts of CBr agonists, making it the perfect potential candidate for the treatment and management of such conditions.
